Molecule Details
| InChIKey | TUYWTLTWNJOZNY-UHFFFAOYSA-N |
|---|---|
| Compound Name | Tezosentan |
| Canonical SMILES | COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.71 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB06558 |
|---|---|
| Drug Name | Tezosentan |
| CAS Number | 180384-57-0 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events. |
Categories: Cardiovascular Agents Receptors, Endothelin Vasodilating Agents
Cross-references: BindingDB: 50143800 CHEMBL61780 ChemSpider: 133242 PubChem:151174 Wikipedia: Tezosentan ZINC: ZINC000003954692